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Abstract  
The past two centuries have witnessed an unprecedented rise in human life 
expectancy. Sustaining longer lives with reduced periods of disability will require 
an understanding of the underlying mechanisms of ageing, and genetics is a 
powerful tool for identifying these mechanisms. Large-scale genome-wide 
association studies have recently identified many loci that influence key human 
ageing traits, including lifespan. Multi-trait loci have been linked with several age-
related diseases, suggesting shared ageing influences. Moreover, mutations that 
drive accelerated ageing in prototypical progeria syndromes in humans point to an 
important role for genome maintenance and stability. Together, these different 
strands of genetic research are highlighting pathways for the discovery of anti-
ageing interventions that may be applicable in humans.  
 
 
Introduction  
Ageing is a seemingly universal biological phenomenon; yet, it is surprisingly 
difficult to define. In essence, ageing is a term used to describe a correlated set of 
declines in functioning with advancing chronological age, which generally begins 
after sexual maturity1,2. Characteristic functional changes occur from the molecular 
and cellular levels, known as ‘biological hallmarks’ of ageing2, through to declining 
physiological homeostasis at the organism level, and lessening abilities to perform 
everyday physical and cognitive tasks. Ageing also increases the susceptibility to 
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many common diseases, and death rates rise approximately exponentially with 
advancing age3.  The main scientific effort in human ageing, termed ‘geroscience’4, 
sees ageing as the primary cause of many chronic diseases of later life, including 
coronary artery disease (CAD), stroke, type 2 diabetes mellitus (T2DM), chronic 
kidney disease, osteoarthritis, Alzheimer disease, and common cancers (such as 
breast, prostate and colorectal cancer). Slowing ageing might prevent many of 
these diseases simultaneously4, as seen in various experimental interventions in 
laboratory models that slow and partially reverse features of ageing (Box 1).  
 Although declining function is characteristic of ageing, rates of decline vary 
enormously; whereas some people die of age-related disease in their sixties, a few 
are still active at 100 years of age and beyond. Understanding the genetic factors 
driving this variability in ageing between people is the main focus of this Review. 
The scope for experimental studies in human ageing is very limited, and 
conventional observational studies are often distorted by confounding factors such 
as smoking or obesity. However, over the past decade, genome-wide association 
study [G] (GWAS)5 results for many phenotypes relevant to ageing have started 
to emerge. Inherited (that is, germline) variant associations are little affected by 
confounding and can provide unique biological insights to clarify whether 
observations in laboratory animals apply to humans. Also, drugs with support from 
human genetic studies for related effects (reported in GWAS and single gene 
disorder databases) succeed from phase I trials to final approval twice as often as 
those without such evidence6. Also, even genes with small-effect genetic variants 
can provide successful drug targets5. Therefore identifying specific variants that 
influence human ageing could help identify suitable targets for antiaging 
interventions in humans.  
 In this Review, we start by outlining the limited proxy measures of human 
ageing currently available. We then discuss recent results from the most robust 
genetic association studies relevant to human ageing, with a focus on ‘multi-trait' 
variants, that is, variants which affect several ageing-related phenotypes 
simultaneously, reflecting the view that correlated changes of ageing have 
common mechanisms. We then describe three key accelerated ageing (progeriod) 
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genetic disorders in humans and review evidence on the accumulation of somatic 
mutations [G] with advancing age, with these two sections providing  insights into 
underlying DNA damage processes that increase cancer risks and may also 
contribute to functional declines in ageing. Evidence is accumulating for age-
related epigenetic7, gene expression and splicing8 changes, but as the causal roles 
of these changes are uncertain, we do not discuss these topics.  
 
[H1] Proxy phenotypes of ageing  
Ideal human ageing phenotypes would measure the underlying biological 
mechanisms and minimize ‘extraneous’ environmental factors9. At the molecular 
level, hallmark biological characteristics of ageing include genomic instability 
(especially DNA damage), telomere attrition, epigenetic alterations, loss of protein 
homeostasis and deregulated nutrient sensing2. At the cellular level, ageing is 
associated with stem cell exhaustion, mitochondrial dysfunction with falling energy 
outputs and increased oxidative stress, as well as altered intercellular 
communications2. Unfortunately, few of these hallmarks can currently be 
measured directly in large enough samples to be analysed in human genetic 
association studies. This means that other age-related phenotypes must serve as 
proxies.  
 
[H2] Lifespan  
Lifespan, the time from birth to death, is an often measured ageing proxy. 
Longevity (used here to mean relatively long lifespans, with a variety of specific 
definitions) is an especially popular ageing measure, as some long-lived people, 
especially centenarians, experience delayed onsets of age-related diseases, with 
compression of morbidity into a smaller proportion of their lifespans10. For example, 
in one study of centenarians, 32% of men and 15% of women had no age-
associated diagnoses at age 100 years11. Exceptional longevity has been defined 
both in terms of arbitrary age cut-off points (for example, ≥85 years, or 
centenarians), and also by, for example, the longest 10% or 1% of lifespans within 
a specified cohort12. Some studies have focussed on exceptional longevity in the 
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context of long-lived families, as there is evidence of increased heritability [G] of 
longevity in this context13.  
 
[H2] Disease and physiological markers  
Clinical diagnoses of age-associated chronic diseases and cancers can provide 
accessible proxy measures of ageing. A summary measure of healthspan [G] 14 
can be made from the duration of life spent without major age-associated 
conditions including myocardial infarction, stroke, diabetes and dementia. Other 
elements can be included in healthspan, such as physical disabilities, cognitive 
impairments and mental wellbeing.   
Biomarkers, currently mostly of clinical measures such as lipid levels, 
inflammation, kidney and liver function15,16 can be combined into indices that 
predict later clinical outcomes in ageing, and can serve as proxy ageing 
phenotypes. Various physiological impairments that accompany ageing are 
measurable, for example, impaired muscle strength17, cognitive function18 and gait 
speed19. Measures of disability and frailty — the age-associated increase in 
vulnerability to stresses and adverse outcomes20 — have also been developed.  
 
[H2] Challenges in studying ageing  
In addition to variations in study design and the vast range of ageing-related 
phenotypes studied, ageing research is bedevilled by a lack of standard 
terminology9. More fundamentally, the validity of essentially all available measures 
of ageing itself is debateable. Results of analyses can depend on the specific 
combination of causal factors driving each phenotype; for example, including 
smoking-induced cancers in disease measures results in smoking-related genes 
emerging as important, whereas including common skin cancers will increase the 
importance of ultra-violet light exposure-related DNA damage pathways. 
Ultimately, human ageing always occurs in the context of common environmental 
exposures in studied populations, and what to include and exclude in proxy 
measures of ageing will likely remain a matter of debate until direct measures of 
the hallmarks of ageing become available.  
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[H1] Heritability of ageing traits  
To what extent are ageing phenotypes driven by genetic variation between 
people? Twin or family-based estimates indicate substantial inherited genetic 
influences. Heritability estimates the ratio of the genetic component to the sum of 
genetic and other (termed ‘environmental’) factors, and is specific to each studied 
population and the environmental exposures current in that population21. Widely 
cited heritability estimates for human longevity from twin studies range from 20% 
to 30%22, but in families with a centenarian, estimates increase to 48% in men and 
33% in women10. However, a recent analysis of millions of family trees estimated 
the heritability of longevity to be 16% (standard error 0.4%), suggesting that 
previous studies may have overestimated the heritability of longevity23. A second 
family tree study found evidence for extensive assortative mating inflating 
heritability estimates, and concluded that the true heritability of longevity is below 
10%24.  
 Common age-related diseases also have substantial heritable components; 
for example, hip osteoarthritis is estimated to be 68% heritable25; type 2 diabetes 
mellitus (T2DM) heritability is estimated at 61% to 78%26; the heritable component 
of Alzheimer disease is estimated to be 58% to 79% (depending on the model 
used)27; and cardiovascular disease heritability has been estimated at 45% to 
69%28. Individual genetic variants have now been identified, mostly by GWAS, that 
are associated with many ageing phenotypes, and the amount of variation in the 
trait attributed to these specific genetic differences can be estimated. These 
genotyped variants cumulatively explained 51.9% of the variation in osteoarthritis 
of the hip29, and 18% of T2DM variation30, but only 8.5% of the variation in parent’s 
age at death31 and 7.1% of Alzheimer disease32. The gap between the higher twin-
study-based heritability estimates for each phenotype and the lower estimates 
from GWAS, often termed the ‘missing heritability’, is attributed partly to lack of 
coverage of several types of genetic variation including rare large-effect variants 
in GWAS, but also to possible overestimates in pedigree-based analyses33.  
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Nonetheless, many ageing-related diseases and traits seem to have 
substantial heritable components. However, heritability estimates do not help 
identify pathways or mechanisms. For genetics to help reveal biological 
mechanisms, find new drug targets, and potentially identify individuals for precision 
medicine treatments, identification of specific human genetic variants associated 
with ageing phenotypes is needed. Such variants have recently been identified 
even for traits with modest heritability. 
 
[H1] Candidate gene studies and GWAS  
Ageing-related genetic variants have been identified mostly in GWAS, which test 
statistical associations between millions of germline variants and a phenotype, 
often in several hundred thousand people5. Smaller-scale candidate studies test a 
subset of variants, but both approaches include multiple statistical tests. As more 
variants are compared it becomes increasingly likely that some will be statistically 
significant just by chance5. To guard against false-positive findings, stringent 
statistical significance thresholds are used and ‘significant’ associations need to 
be replicated in independent samples. In reviewing ageing studies, we therefore 
prioritize the strongest available associations (preferably at genome-wide 
statistical significance34 p<5*10-8), especially those with independent replication. 
 
[H2] Human lifespan and longevity 
The most robust identifications of lifespan-related variants currently come from 
recent, very large cohorts, such as the UK Biobank35, which includes 500,000 
community volunteers. These studies have focused on parental age at death, as 
offspring health status and survival are associated with parental lifespan. For 
example, an analysis of Health and Retirement study (USA) data covering 
participants aged 51-61 years at baseline followed for 18 years, all-cause mortality 
consistently declined by 19% for each decade their mothers survived beyond age 
65 years (14% per decade for fathers)36. Also, study participants had progressively 
lower incidence of cardiovascular disease and cancers36, as well as reduced rates 
of cognitive decline37, with increasing parental survival. A study of 186,151 non-
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adopted UK Biobank participants followed for up to 6 years produced similar 
results, with declines in all-cause mortality of 16% per decade of mothers survival 
≥70 years of age (hazard ratio [HR]: 0.84; 95% confidence interval [CI]: 0.79 to 
0.89) and 17% (HR: 0.83; 95% CI: 0.78 to 0.89) for father’s survival. Cause specific 
mortality declined with advancing parental ages especially for Coronary Heart 
Disease (20% per decade with decades of mother’s age ≥70 years: HR: 0.80; 95% 
CI: 0.68 to 0.95; and 21% for father’s HR: 0.79; 95% CI: 0.63 to 0.98), but declines 
in cancer mortality (HR: 0.92; 95% CI: 0.90 to 0.95) were also present38.  
 Several GWAS have been reported for parents’ age at death (or attained 
age thus far) in UK Biobank alone31,39,40, and additionally two meta-analyses of UK 
Biobank with other cohorts have also been published: the “LifeGen consortium” 
included data from 160,000 study participants from 25 cohorts in addition to UK 
Biobank41, and a separate analysis using 300,000 individuals with pedigree data 
from AncestryDNA42 was meta-analysed with UK Biobank. The ages at death of 
the parents (or current age if still alive) studied in the LifeGen analysis41 varied 
from 40 to 107 years, while the AncestryDNA42 lifespans ranged from 40 to 120 
years. Six genetic loci were identified in both studies for longer parental lifespan 
(Table 1), with 12 additional loci identified only in one or other study. Many of the 
implicated variants have been linked previously to cardio-metabolic conditions 
(mostly myocardial infarction and diabetes mellitus), with some linked to 
Alzheimer’s disease, autoimmunity and cancer risk41, thus reflecting the more 
common causes of death in older people. 
Gene–environment interactions were evident for some variants. For 
example, rs1051730 is in an exon of CHRNA3 - encoding a nicotinic acetylcholine 
receptor subunit - and the lifespan-reducing allele is correlated with rs8042849, 
which increases susceptibility to nicotine dependence43, and likely reduces 
lifespan by increasing smoking exposure. Interestingly, this association was 
stronger for fathers’ than mothers’ age at death, perhaps due to gender differences 
in smoking in the parental generation31. Effect sizes for all lifespan-associated 
variants were modest, with the largest per allele effect for the APOE ɛ4 variant 
accounting for 1.06 years of parental lifespan41. The smallest-effect variant 
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identified by LifeGen was intronic in the HTT gene (also known as Huntingtin), 
although the relationship of this variant to Huntington disease mutations is unclear. 
Of the 18 variants identified, only one (in APOE) was exonic and affected the 
coding sequence, suggesting mainly regulatory effects, as is common for 
polygenic traits44.  
In a UK Biobank GWAS, sub-analyses of the participants’ genotypes in the 
top 10% of parents’ survival (with survival to ≥90 years in mothers and ≥87 years 
in fathers) produced results similar to overall lifespan analyses39: four loci 
remained associated at genome-wide significance (APOE, CHRNA3, LPA and 
CDKN2B-AS1), with the others remaining nominally significant (all with p-values 
<0.002). Two additional loci (MC2R and USP2-AS1) were significant for top 10% 
survival in the analysis of parents’ lifespan. In an analysis of centenarian parents 
the results were consistent, with similar genotype-lifespan effect sizes39. Although, 
numbers here were small - with only 1,181 participants having at least one 
centenarian parent - meaning only the APOE locus was genome-wide significant39. 
Thus, lifespan-associated variants can also be important for longevity, although 
some variants may be specific to longevity.  
 
[H3] Genetic associations with longevity 
GWAS have also directly compared long-lived individuals (aged ≥90 years) to 
younger controls (aged <65 years, although definitions vary45–48, as reviewed 
recently elsewhere3). The most recent meta-analysis in 2019 included 11,262 
participants who survived beyond the 90th percentile48. The most robust findings 
have been for the APOE haplotypes, with ɛ4 being less common in long-lived and 
APOE ɛ2 more common (versus the ɛ3 haplotype). The two APOE haplotypes 
have similarly inverse associations with Alzheimer’s disease32 and cardiovascular 
disease49. Apolipoprotein E (APOE) is involved in the transport of cholesterol and 
other lipids to cells; in the brain, this function is important in neural cell membrane 
and synapse maintenance and repair50, although the full mechanisms causing 
Alzheimer disease remain elusive. A recent study showed that the APOE ɛ4 
haplotype was associated with excess mortality even within the longest lived 1% 
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of survivors, and that the ɛ2/ɛ2 or ɛ2/ɛ3 haplotypes were associated with modestly 
decreased mortality within the longest lived 1% of survivors51. The recent 2019 
meta-analysis of longevity GWAS48 identified a new locus highlighting GPR78: the 
identified longevity-variants have not previously been identified in GWAS for other 
traits, but the gene (encoding G Protein-Coupled Receptor 78) has been implicated 
in traits including lung function52 in the GWAS catalog53. 
The study of extreme longevity has been refined recently by the finding that 
heritability is higher in those who are part of long-lived families and that 
environmental factors seem to be more important in sporadic longevity13. A GWAS 
in 583 ‘Long Life Family Study’ families (covering the long-lived individuals and 
offspring, which unusually also included predicted longevities) confirmed 
associations at the APOE locus and also identified a variant (rs1927465) between 
MYOF (which encodes myoferlin) and CYP26A1 (which encodes cytochrome 
P450 family 26 subfamily A member 1) genes at genome-wide significance54. At 
the time of writing, rs1927465 has not been reported in the GWAS catalogue for 
other phenotypes.  
A much studied set of extreme longevity-associated variants have been 
reported in the FOXO3A gene, which encodes a transcription factor that influences 
energy metabolism, cell cycle regulation and inflammation, and is important in 
modulating the effect of calorie restriction on longevity in model organisms55. In 
the longest lived 1% of survivors, 17 FOXO3A variants were more common 
compared with controls (n=2,072 aged ≥96 years versus <96 years); the strongest 
association was found for the variant rs4946935 (odds ratio 1.20 for extreme 
longevity, p=3.2*10−5)56. However, none of these 17 FOXO3A variants affected 
death rates for the younger 99% of lifespans, which is consistent with no FOXO3A 
variants reaching genome-wide significance in the large parents lifespan GWAS 
discussed above39,41.  
 The evidence on mostly candidate gene variants has also been reviewed 
(comparing groups aged ≥85 years including centenarians versus those aged <85 
years, most <60 years)57, with seven claimed longevity variants found to be weakly 
or not associated with survival to age ≥85 years. It has been argued that different 
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populations may have different exceptional longevity variants due to particular 
environmental exposures and ancestry-specific genetic differences58, providing a 
possible explanation for the limited replication of claimed exceptional longevity 
variants. Another explanation might be the relatively modest sample sizes (often 
fewer than 10,000 long-lived individuals), or potential false-positive findings of 
some associations.  
None of the variants identified thus far as being associated with (extreme) 
longevity seem essential (that is, not all long-lived people harbour them) and none 
seem sufficient to achieve longevity (all are fairly common in groups who die 
earlier). This finding is consistent with the notion that the heritable component in 
the longest 10% for survival is a quantitative trait13 likely affected by large numbers 
of small effect variants. 
 [H2] Reproductive lifespan in women  
Women are unusual compared with other female mammals in having a total 
lifespan that is substantially longer than their reproductive lifespan. In a GWAS of 
age at menopause59, 56 variants were identified, with approximately two-thirds of 
loci implicated in the DNA damage response (DDR)60. As discussed below, 
unrepaired DNA damage might be a major driver of overall ageing. Also, some of 
the menopause associated variants have effects on the hypothalamic–pituitary 
axis, which controls many hormone levels. A polygenic risk score [G] for each 
individual in a study population can be calculated by summing the number of risk-
increasing alleles (weighted by published effect size) each participants carries: a 
genetic risk score for age at menopause was not associated with parental 
lifespan31 in the UK Biobank. Menopause associated variants may therefore have 
limited effects on human ageing more generally.  
 
[H2] Muscle strength 
Decreasing muscle strength is a common feature of ageing and is associated with 
increased risks of cardiovascular disease and mortality, even in those aged <60 
years61. A GWAS of the full range of strength (measured as grip strength)62 
identified several lead variants in or near genes implicated in the structure and 
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function of skeletal muscle fibres, neuronal maintenance and signal transduction 
in the central and peripheral nervous systems. Whether low muscle strengths in 
older people are driven by the same variants is unclear, but a targeted study of the 
human leukocyte antigen (HLA)-mediated autoimmunity-associated region 
reported associations with low muscle strength in 60- to 70-year-olds63 without 
autoimmune disease.  
 
[H2] Cognitive impairment  
Normal ageing is often associated with impairment in some cognitive tests, even 
in the absence of dementia. Cognitive impairment has a number of risk factors, 
such as hypertension, that are potentially treatable if caught early64. The largest 
recent genetic study of general cognitive function in >300,000 people identified 
>100 loci, implicating genes expressed in the brain, but also including loci 
associated with traits such as hypertension, suggesting systemic effects on 
cognition65. A recent genetic analysis of decline in cognitive ability in 1,091 people 
found that the APOE ɛ4 allele alone was the strongest predictor compared to 
polygenic risk scores for CAD, educational attainment and other traits66. Another 
study in 1,176 men in their 50s67 found that genetic risk of Alzheimer disease was 
associated with mild cognitive impairments. Although these studies were limited 
by small sample sizes, cognitive impairment is evidently a complex multifactorial 
process in which inherited variation has a role in addition to lifestyle and other 
health-related factors 68. 
 
[H2] Age-related disease variants  
Many GWAS of age-related diseases have been reported, with thousands of 
variants now identified5. One of the earliest successful GWAS identified variants 
influencing age-related macular degeneration (AMD)69, the most common cause 
of blindness in the western world. Two larger-effect loci were found: one mapped 
to CFH, which encodes complement factor H in the complement inflammation 
cascade, and ARMS2 (also known as HTRA1), which is involved in extracellular 
matrix turnover. Both variants were associated with more than 2.5-fold differences 
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in AMD risk in a recent large study70. The effect sizes of these variants contrast 
with many other common disease-associated variants, for which effect sizes are 
typically small, often with <10% differences in risk5. 
 
[H2] Genetic variation across common diseases 
The duration of the disease-free period of life (that is, ‘healthspan’) is an important 
measure of the physical health aspects of ageing well, and was recently studied in 
UK Biobank participants aged 37–73 years14. All available age-associated 
diagnoses were included and a notable variant found to be associated with 
healthspan had previously been implicated in skin cancers71. As skin cancers 
represent the most common cancer type72, the prominence of skin cancer variants 
in the results of this composite healthspan measure is unsurprising. However, skin 
cancer risk is related to high levels of sun exposure73, which is a highly variable 
behavioural exposure, especially between older people. Thus, composite 
measures may highlight common exposures rather than necessarily identifying 
shared ageing mechanisms.  
An alternative to examining composite measures of disease is to examine 
common loci associated with several different diseases of ageing. This approach 
is in line with the geroscience view that biological mechanisms of ageing underlie 
many of the diseases that occur in later life. All the most common diseases of 
ageing, including Alzheimer disease, CAD, chronic kidney disease, osteoarthritis, 
stroke, T2DM, and common cancers, have been extensively studied in GWAS. Of 
note, this list excludes diseases with known dominant environmental risk factors, 
for example, lung cancer and chronic obstructive pulmonary disease, risks of both 
being strongly related to smoking. When analysed, 961 genome-wide significant 
variant associations had been reported for our list of included common age-related 
conditions (Supplementary tables 1 and 2, see the GWAS catalog for a 
continuously updated database of GWAS findings). As biological pathways of 
ageing likely affect susceptibility to many of these diseases of later life, finding 
genetic variants associated with several pathways simultaneously should help 
reveal underlying ageing mechanisms.  
 13 
 
 
[H3] Genetic correlation  
One approach to explore shared genetic effects is to estimate genetic correlation 
— the degree of genetic overlap between pairs of traits — using GWAS results74,75 
(Fig. 1, Supplementary table 3). This method uses linkage disequilibrium (LD) [G] 
information in conjunction with the variant–trait associations to compute cross-trait 
LD score regression estimates of shared heritability (genetic correlation), and is 
well suited to analyses of complex traits with many thousands of small-effect 
variants that do not necessarily reach genome-wide significance74. Our analyses 
show that CAD, osteoarthritis, T2DM and stroke GWAS results correlated 
negatively with parental longevity, with 40–60% overlap (see Supplementary Table 
3 for details) suggesting strong shared mechanisms. Alzheimer disease GWAS 
results had a moderate negative correlation with lifespan, but breast cancer and 
prostate cancer variants were not correlated with lifespan (Supplementary Table 
3) suggesting that shared variants across diseases of ageing are important but not 
for all phenotypes.  
 
[H3] Genetic risk score associations  
An alternative approach to revealing shared mechanisms is to test whether a 
polygenic risk score for a biomarker is associated with a phenotype. For example, 
increasing parental lifespan was associated with lower genetic risk of raised LDL-
cholesterol levels and systolic blood pressure31. Also, a 7-month shortening in 
parental lifespan per unit of genetically determined increasing body mass index 
(BMI) has been reported40. This adverse effect of increased BMI contrasts with 
claims that being obese or overweight is beneficial in older people76 but is 
consistent with the success of calorie restriction in lengthening survival in animal 
models (Box 1). Also, high numbers of senescent cells accumulate in adipose 
tissue with age, especially around internal organs77,78. The paradoxical obesity 
claims seem to be generated in part by weight loss resulting from serious disease 
in older people. In other words, older people with obesity have to be fairly healthy 
to maintain their obesity. Longer-term observational analyses minimizing the 
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effects of diseases that cause weight loss show that 65–74-year-olds with obesity 
are at higher risk of dementia79 and have higher death rates80. However, whether 
avoiding obesity is important to reach centenarian status remains unclear81.  
 
[H1] Shared genetic effects on ageing phenotypes  
As noted, there were 961 genome-wide significant variant–trait associations 
across selected age-related diseases (Supplementary table 2). Given our focus on 
variants that affect several age-related diseases simultaneously — as these are 
more likely to reveal underlying ageing mechanisms — we searched for loci 
associated with three or more of selected age-related traits (with variants 
separated by <250 kb). We found 22 such ageing multi-trait loci; of these, 12 loci 
had variants in LD (R2>0.6) with each other (Supplementary tables 4 and 5). One 
of those loci was APOE, which as described above has been associated with 
Alzheimer disease, CAD, as well as exceptional longevity and parental lifespan. 
Two other loci (LPA and LDLR) contain variants influencing blood lipid levels82 and 
cardiovascular traits49. The disease associations of the remaining nine multi-trait 
loci are more diverse (Fig. 2) and therefore more likely linked to ageing 
mechanisms, as we discuss below. 
 
[H2] The CDKN2A/B and CAS8 loci 
The CDKN2A/B locus (also known as the 9p21 locus) contains genes that produce 
the p16ink4a, p14arf and p15ink4b tumour suppressor proteins (Fig. 3) and the 
long non-coding RNA (lncRNA) CDKN2B-AS1 (also known as ANRIL), which 
regulates CDKN2A/B expression83. Variants in or near these genes have been 
associated with multiple diseases, including cardiovascular conditions49, T2DM30, 
cancers84,85, endometriosis86, glaucoma and related optic disc traits87, as well as 
blood cell count88 and parental lifespan41 (see further details and references in 
Supplementary table 6). Cell senescence is often accompanied by expression of 
p16ink4a (CDKN2A), and clearance of CDKN2A-expressing cells in mice89 
attenuated age-related deterioration in the eye, kidney, heart, and fat, with no 
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overtly adverse effects [see Box 1]. Efforts to develop interventions to remove 
senescent cells in humans are being actively pursued90. 
Interestingly, the disease-associated variants in the CDKN2A/B locus are 
not in coding areas (Fig. 3, see Supplementary table 6 for details), and there is 
limited overlap in variants associated with different traits: for example, variants 
associated with vascular disease, such as rs94479749, are not associated with 
diabetes mellitus30, and vice versa. This locus may therefore be an example of 
genetic variation influencing cell-type-specific regulation of genes important in 
human ageing.  
Another multi-trait locus of potential importance for ageing is CASC8 
(cancer susceptibility candidate 8), which is a lncRNA containing variants 
associated with breast84, prostate85 and colorectal91 cancers. A T2DM-associated 
variant is located nearby (<250 kb) in CASC1130. Both CASC8 and CASC11 are 
upstream of MYC, an oncogene known to be regulated by lncRNAs92. This 
observation suggests a similar mechanism to that of the lncRNA CDKN2B-AS1, 
whereby genetic variants affect regulation of senescence-related genes via 
lncRNAs. 
 
[H2] Telomere-related genetic variants  
Four unique genetic variants mapped to the telomerase gene TERT were 
associated with breast, colorectal and prostate cancer risk in GWAS84,85,91. 
Telomerase is involved in telomere maintenance, the end fragments of 
chromosomes which shorten with each cell cycle. Telomere shortening is a major 
contributor to replicative senescence93 and therefore a biological hallmark of 
ageing. In humans, telomere length measured in blood has a strong inherited 
genetic component, with heritability estimates of 34–82%94. GWAS have linked 16 
inherited variants to human leukocyte telomere length95, including variants in the 
genes encoding telomerase and telomere-protective protein genes (TERC, TERT, 
NAF1, OBFC1 and RTEL1)96. A Mendelian randomization [G] study of genetic 
variants associated with longer telomeres reported reduced risks of CAD and 
interstitial lung disease but increased risks of several forms of cancer95, suggesting 
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a trade-off between risks of cancer and chronic age-related disease. No 
association was found between genetic predisposition to longer telomeres and 
parental longevity31, suggesting that the positive and negative effects on health 
might cancel themselves out for overall survival. A recent analysis suggested that 
telomere variants were also not associated with the top 1% of parental longevity, 
or measures of cognitive or physical function in older UK Biobank participants97.  
 
[H2] SH2B3: a partial Drosophila homologue   
In humans, the SH2B3 gene encodes lymphocyte adaptor protein LNK, which is 
an intracellular modulator of the erythropoietin receptor, the stem cell factor 
receptor c-Kit and JAK298. GWAS have implicated the SH2B3 locus and nearby 
genes (ATXN2, BRAP) in many diseases49,91,99. The likely causal variant in SH2B3 
associated with shorter parental longevity39,100 is a missense variant (rs3184504-
T) predicted to disrupt LNK protein functioning. The T allele is more common in 
autoimmune and cardiovascular conditions101 and myeloproliferative cancers98, as 
well as breast, colorectal and lung cancers102 (compared to the ‘normal’ functioning 
C allele). By contrast, the C allele of rs3184504 is more common in those reaching 
the longest lived 10%39 and 1% of lifespan103. The INTERVAL GWAS of human 
blood protein levels found that the rs3184504 C allele is associated with reduced 
levels of vascular cell adhesion protein 1 (VCAM-1), which functions in leukocyte 
recruitment in the cellular immune response, in angiogenesis104, and influences 
development and spread of cancers105. Interestingly, the rs3184504 C allele is also 
associated with increased cardiovascular risk49,99 but decreased cancer risk91, 
again suggesting a trade-off between chronic disease and cancer mechanisms in 
ageing (Supplementary table 2).  
 In Drosophila melanogaster, the SH2B gene is an insulin-like growth factor 
(IGF-1) and energy balance signalling modulator, and an SH2B loss-of-function 
mutant was long-lived in starvation conditions, through increased carbohydrate 
stores106. Modifications to the IGF pathway in model organisms, from worms to 
mice, produce dramatic lifespan extension akin to those seen in dietary restriction 
experiments107,108 (Box 1). However, whereas the human SH2B1 and SH2B2 
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homologues of SH2B are important for IGF-1 signalling, SH2B3 is not an important 
IGF-1 regulator109. The SH2B3 locus is therefore clearly important in human 
ageing but likely through more specialized mechanisms than those targeted in 
SH2B model organisms for ageing, underlining the need for caution in generalizing 
from ancestral genes in model organisms to humans.  
 
[H2] The HLA region and ABO blood groups 
The histocompatibility complex gene group on chromosome 6 encodes HLA 
genes, which mediate chronic inflammatory pathways in autoimmune and 
infectious diseases110. Genetic variants near HLA-DQA1 are associated with 
lifespan41, Alzheimer disease32, prostate cancer85 and T2DM30, and also alter 
levels of the circulating inflammation marker C-reactive protein111. An HLA variant 
has also been linked to low muscle strength63, suggesting a role in the 
development of physical impairments in human ageing. These associations 
suggest that overlaps exist between autoimmune inflammatory mechanisms and 
the chronic inflammation commonly seen in ageing.  
Somewhat similar are the ABO antigens, which determine blood group 
types. ABO antigens are expressed on a wide range of tissues and cell surfaces, 
and are important in infectious disease susceptibility, tumorigenesis and 
cardiovascular disease112. Genetic variants in the ABO locus have been 
associated with T2DM30, breast cancer84 and stroke99 as well as altered levels of 
the circulating inflammation marker C-reactive protein111. In each study, the O 
(recessive) blood type was protective later in life (compared to the other blood 
groups) but also seemed to increase the risk of haemorrhages at younger ages112, 
an apparent example of antagonistic pleiotropy [G] (Box 2). 
 
[H2] Obesity, T2DM and cancer loci 
Variants in the TCF7L2 locus are linked to T2DM30, breast84 and colorectal 
cancer91. TCF7L2 is involved in β-cell proliferation and insulin production113, and 
variants in this locus are also associated with increased obesity114, which itself is 
a driver of T2DM and many cancers115. There are also other multi-trait loci linked 
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to T2DM and multiple cancers, including ZMIZ130,84,91, VEGFA30,85, and FTO30,84 
(Supplementary table 5). These loci highlight the importance of adiposity as an 
accelerator of ageing, which is consistent with the accumulation of senescent cells 
in adipose tissue77 and the success of caloric restriction in lengthening life in many 
laboratory models (Box 1).  
 
[H1] Inferring mechanisms of aging from mutations   
The integrity and maintenance of the genome appears to be strongly connected 
with aging and longevity. Mutations in genes that affect DNA repair capacity and 
DNA maintenance cause progerias, and there is evidence that the accumulation 
of somatic DNA mutations may be associated with phenotypes of aging and 
contribute to chronic diseases. 
 
[H2] Single-gene disorders of accelerated ageing 
Segmental progerias are genetic diseases that exhibit many clinical manifestations 
similar to those that develop with ageing but which manifest earlier in life116. 
Prototypical examples of these syndromes are Werner syndrome (Online 
Mendelian Inheritance of Man (OMIM) #277700), Hutchinson–Gilford progeria 
(OMIM #176670) and Cockayne syndrome (OMIM #216400). The study of these 
conditions can provide important hints on the genetic and biological mechanisms 
that drive the ageing process.  
 
[H3] Clinical phenotypes  
Patients with Werner syndrome develop normally but lack a pubertal growth spurt 
and later develop skin atrophy, loss of subcutaneous adipose tissue, loss and 
greying of hair, T2DM, cataracts, osteoporosis, early loss of fertility, severe 
arteriosclerosis, peripheral neuropathy and cancer117. Interestingly, cells from 
patients with Werner syndrome exhibit a shortened replicative lifespan118. Patients 
with Hutchinson–Gilford progeria are normal at birth but then grow slowly and 
develop baldness, loss of eyelashes and eyebrows, prominent eyes, convex nasal 
bridge and a small jaw, loss of subcutaneous fat, musculoskeletal abnormalities 
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and premature cardiovascular pathology119. Patients with Cockayne syndrome 
display photosensitivity and developmental failure after 1 year of age, 
underrepresented subcutaneous adipose tissue, premature decline of cognitive 
function and cardiovascular pathology, leading to a median survival of 
approximately 12 years120.  
 
[H3] Genetics  
Interestingly, all three syndromes arise from genetic mutations that affect genomic 
structure and function through DNA repair, nuclear architecture and the fidelity of 
DNA replication121. In particular, Werner syndrome is caused by mutations of the 
WRN gene, which encodes a member of the RecQ family of helicases that is 
involved in DNA recombination, replication and telomere maintenance117. Over 
90% of Hutchinson–Gilford progeria cases are caused by de novo heterozygous 
mutations in the LMNA gene, which encodes the proteins lamin A and lamin C 
through alternative splicing122. Lamin A and C are assembled to form a matrix on 
the inner surface of the nuclear membrane the integrity of which is important for 
DNA maintenance, such as DNA double-strand break repair122. Of note, in 
Hutchinson–Gilford progeria, a point mutation within LMNA exon 11 leads to the 
production of progerin, a mutant protein responsible for the fragility of the nuclear 
envelope, with rearrangement of heterochromatin similar to what is often see in 
fibroblast nuclei from older persons123. Small amounts of progerin accumulate with 
normal ageing and may contribute to age-related cardiovascular diseases124. 
Finally, Cockayne syndrome is caused by mutations in the ERCC8 and ERCC6 
genes, which encode the CSA and CSB proteins, which play central roles in 
transcription-coupled nucleotide excision repair that occurs at specific secondary 
DNA structures125.  
Overall, prototypical progerias suggest that a progressive loss of genetic 
and genomic integrity may contribute to the ageing process. So far, data on 
progerias suggest that mechanisms of DNA repair and maintenance are important 
for health maintenance, but whether they configure true accelerated aging 
syndromes remains questionable. A key question that follows is whether common 
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variants mapped to these same progeria genes are important for the common traits 
in the general population. The GWAS catalog53 reports that variants in the Werner 
syndrome-associated WRN gene are associated with cognitive function and 
educational attainment126; variants in the Hutchinson-Gilford-associated LMNA 
gene are associated with white blood cell counts52 and height52; and variants in the 
Cockayne syndrome-associated ERCC8 gene affect age at smoking initiation127. 
No variants in ERCC6 have reached genome-wide significance in studies 
published in the GWAS catalog (as of 19 July 2019).  
 
[H3] Hereditary haemochromatosis  
Other lower penetrance genetic disorders also provide insights into the 
mechanisms of ageing. A prototypic example is iron overload due to hereditary 
haemochromatosis, which causes widespread oxidative damage128. The main 
homozygous HFE p.C282Y mutations (present in approximately 1 in 150 people 
of Northern European ancestry) is associated with increased incidence of arthritis, 
T2DM and liver disease129, typically after age 40 years, as well as low muscle 
strength and chronic pain in 60–70 year olds130. Treatment (withdrawing blood) is 
effective and safe but often delayed because early manifestations are mistaken for 
‘normal’ ageing. This mutation probably became common during the transition 
from hunter–gatherer to agricultural living, when low meat intake made increased 
dietary iron absorption advantageous, especially for pregnant women. This 
disease therefore supports the antagonistic pleiotropy theory of ageing, being a 
variant selected to enhance reproduction but that has adverse effects later in life 
(Box 2). More work is needed to identify other mutations with later life effects131, 
including rare mutations. 
 
[H2] Somatic mutations in human ageing  
As several of the progerias (and age at menopause) are caused by genes involved 
in DNA repair and genomic stability, an obvious related question is whether 
accumulation of somatic mutations are important drivers of ageing132. There is now 
increasing evidence from single-cell and small sample size sequencing studies 
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that unrepaired or incompletely repaired somatic mutations accumulate with 
ageing, including in oncogenes, and can lead to clonal expansion [G] of mutated 
cells133. Stem cells generate new cells used for tissue repair, remodelling or 
renovation, and therefore somatic mutations in stem cells have the highest 
potential for clonal expansion. A study of small intestine, colon and liver samples 
from human donors aged 3–87 years showed an accumulation of approximately 
40 somatic mutations per year in stem cells134. A study of human B lymphocyte 
somatic mutations, in both coding and regulatory regions, found <500 per cell in 
neonates, rising to >3,000 per cell in centenarians135. Similar accumulations of 
somatic mutations with age have also been reported for satellite cells in muscle136. 
Similarly, sequencing of oesophageal micro-samples showed age-associated 
accumulation of mutations, with middle-aged and elderly donors having cancer-
associated mutation clones (including in the TP53 cancer control gene and 
NOTCH1, which encodes a tissue development regulator) covering a majority of 
the epithelium, with evidence that the burden of mutations is higher in heavy 
drinkers and smokers137,138. There is some evidence that clonal expansion of 
somatic mutations in haematopoietic stem cells is associated with a higher risk of 
cardiovascular diseases and leukaemia139, but whether it is also linked to biological 
ageing has not been demonstrated. However, it remains unclear how important 
these somatic mutations are for longevity; one study of 864 people aged 80–105 
years found that somatic mutations in genes linked to clonal expansion of 
hematopoietic stem cells did not compromise 10-year survival140.  
 
[H3] Acquired mitochondrial genetic variants  
Mitochondria have their own DNA (mtDNA), a circular 16.5 kb double-stranded 
loop of DNA that encodes 13 protein subunits of the electron transport chain and 
is uniquely inherited from mother to offspring141.  Each cell contains many 
mitochondria and each one contains many mtDNA copies; therefore, multiple 
mutations can coexist in the same cell, a phenomenon known as heteroplasmy142. 
Maternally inherited mtDNA variants can cause mitochondrial diseases143. 
Interestingly, mitochondrial inherited diseases are often characterized by 
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progeroid characteristics, such as neurodegenerative and neuromuscular 
manifestations144, suggesting that mitochondrial dysfunction may contribute to 
ageing. Indeed, de novo mtDNA mutations occur at random and accumulate 
unrepaired in several tissues at a rate substantially higher than nuclear DNA, 
probably because of the direct exposure to reactive oxygen species (ROS), lack 
of true histones and limited DNA repair mechanisms145–147. If the mutational load 
reaches a certain threshold it can affect the efficiency of oxidative phosphorylation 
and increase the production of ROS, especially in individuals who already have 
inherited mtDNA mutations148. This accumulation of mtDNA variants may cause 
many of the phenotypes of ageing, including metabolic, neurodegenerative and 
neoplastic diseases148. In support of this hypothesis, a knock-in mouse mutation 
that compromises the proofreading ability of mtDNA polymerase and results in 
massive accumulation of mtDNA mutations with age was associated with reduced 
lifespan and early development of ageing phenotypes149. Indeed, the frequency 
and quantity of mtDNA mutations is higher in organs of patients with chronic 
diseases that specifically affect those organs but is particularly evident in 
neurodegenerative diseases, such as Alzheimer, Parkinson and Huntington 
diseases150,151.  
 
Conclusions and future perspectives  
Despite still being in the early phases of genetic discovery in human ageing, the 
available evidence supports major insights. The emerging picture (Fig. 4) is one of 
human ageing being driven by the balance of damage and repair processes, 
influenced by both environmental exposures and genetic variation between 
people. The hallmark pathways of ageing were identified mainly from animal 
models152, but a role for some of these mechanisms is evident in GWAS results: 
several multi-trait loci including CDKN2A/B, SH2B3, TERT, as well as inflammation 
and obesity-related variants, are linked to hallmark pathways of ageing. In some 
cases, variants in these loci result in trade-offs between cancer and chronic 
disease risks. DNA repair mechanisms have emerged as important for female 
reproductive ageing as well as key progeria syndromes, and evidence is 
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accumulating that unrepaired somatic mutations may be of fundamental 
importance in human ageing.  
In addition to the multi-trait loci, many variants showing disease-specific 
effects are also important in how humans age. For example, the vascular disease 
effects of lipid-altering variants or the cartilage-specific variants involved in 
osteoarthritis29 suggest that both shared ageing mechanisms and disease-specific 
mechanisms are important in human ageing. Disease-specific genetic and 
environmental risks help explain the great variability of ages of disease onsets and 
comorbidities seen across older populations.  
Will knowledge of ageing-related genetic variation ever yield personal 
predictions for later life? A whole-genome risk score from the 1 million lifespan 
parental longevity GWAS, comparing individuals in the top and bottom deciles, 
was associated with 3–5 year increased life expectancy41. This observation is 
promising, although this variation constitutes only a small proportion of the 
variation seen in human lifespan. Also, better control of potentially modifiable 
health risks that have an important role in ageing, such as obesity, blood pressure 
and cholesterol levels, could alter genetic predictions.  
Genetic studies of human ageing are currently limited to the study of proxy 
measures of biological ageing. For many variants implicated in genetic association 
studies, exact effect mechanisms are unproven, and the general assumption that 
effects are mediated through the nearest gene is not always true153. The effects of 
some of the multi-trait loci highlighted may be through separate variants and/or 
different pathways. Much work is needed to establish the biological mechanisms 
influenced by GWAS-identified variants, including in loci that affect multiple traits.  
In the coming years, much more will be learned about human ageing, 
hopefully with better phenotyping of the biological hallmarks of ageing. Larger 
sample sizes as well as DNA sequencing and linked studies of proteomics, gene 
expression and epigenetics will capture more of the genetic variation between 
individuals, and will help identify the mechanisms of effect of these genetic 
variations. Thus far, most of the evidence is from European ancestry groups, and 
studies of others — especially African ancestry groups, who have greater genetic 
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heterogeneity — are likely to extend findings154. It seems probable that much more 
evidence of ageing pathways will be found, including novel pathways that might 
provide intervention targets or offer new prevention opportunities. There remains 
ample scope for using inherited variants to understand human ageing 
mechanisms. Overall, human genetics is likely to continue to play a major role in 
our growing insights into how we age and in identifying ways in which we might 
slow ageing, and thus help more people to age well.  
 
References  
1. Partridge, L. & Mangel, M. Messages from mortality: The evolution of death 
rates in the old. Trends Ecol. Evol. 14, 438–442 (1999). 
2. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. 
The Hallmarks of Aging. Cell 153, 1194–1217 (2013). 
 
This paper reviews the evidence for nine key mechanisms that are 
characteristic of mammalian ageing. 
 
3. Partridge, L., Deelen, J. & Slagboom, P. E. Facing up to the global 
challenges of ageing. Nature 561, 45–56 (2018). 
4. Kennedy, B. K. et al. Geroscience: Linking Aging to Chronic Disease. Cell 
159, 709–713 (2014). 
 
This paper provides an overview of geroscience, which argues that many 
chronic diseases share underlying ageing mechanisms which should 
be targeted to improve overall health in later life. 
 
5. Tam, V. et al. Benefits and limitations of genome- wide association studies. 
Nat. Rev. Genet. (2019). doi:10.1038/s41576-019-0127-1 
6. Nelson, M. R. et al. The support of human genetic evidence for approved 
drug indications. Nat. Genet. 47, 856–860 (2015). 
 
 25 
 
This study found that development of drugs supported by genetic evidence 
of mechanism could double the success rate. 
 
7. Declerck, K. & Vanden Berghe, W. Back to the future: Epigenetic clock 
plasticity towards healthy aging. Mech. Ageing Dev. 174, 18–29 (2018). 
8. Harries, L. W. et al. Human aging is characterized by focused changes in 
gene expression and deregulation of alternative splicing. Aging Cell 10, 
868–78 (2011). 
9. Carnes, B. A. What is lifespan regulation and why does it exist? 
Biogerontology 12, 367–374 (2011). 
10. Sebastiani, P. & Perls, T. T. The genetics of extreme longevity: Lessons 
from the New England centenarian study. Front. Genet. 3, 277 (2012). 
11. Evert, J., Lawler, E., Bogan, H. & Perls, T. Morbidity profiles of 
centenarians: survivors, delayers, and escapers. Journals Gerontol. - Ser. 
A Biol. Sci. Med. Sci. 58, 232 (2003). 
12. Sebastiani, P. et al. Four Genome-Wide Association Studies Identify New 
Extreme Longevity Variants. J Gerontol A Biol Sci Med Sci 72, 1453–1464 
(2017). 
13. van den Berg, N. et al. Longevity defined as top 10% survivors and beyond 
is transmitted as a quantitative genetic trait. Nat. Commun. 10, (2019). 
14. Zenin, A. et al. Identification of 12 genetic loci associated with human 
healthspan. Commun. Biol. 2, 300889 (2019). 
15. Levine, M. E. Modeling the rate of senescence: Can estimated biological 
age predict mortality more accurately than chronological age? Journals 
Gerontol. - Ser. A Biol. Sci. Med. Sci. 68, 667–674 (2013). 
16. Liu, Z. et al. A new aging measure captures morbidity and mortality risk 
across diverse subpopulations from NHANES IV: A cohort study. PLoS 
Med. 15, e1002718 (2018). 
17. Matteini, A. M. et al. GWAS analysis of handgrip and lower body strength 
in older adults in the CHARGE consortium. Aging Cell 15, 792–800 (2016). 
18. Gow, A. J. et al. Stability and change in intelligence from age 11 to ages 
 26 
 
70, 79, and 87: the Lothian Birth Cohorts of 1921 and 1936. Psychol. Aging 
26, 232–40 (2011). 
19. Ben-Avraham, D. et al. The complex genetics of gait speed: genome-wide 
meta-analysis approach. Aging (Albany. NY). 9, 209–246 (2017). 
20. Fried, L. P. et al. Frailty in Older Adults: Evidence for a Phenotype. 
Journals Gerontol. Ser. A Biol. Sci. Med. Sci. 56, M146–M157 (2001). 
21. Tenesa, A. & Haley, C. S. The heritability of human disease: Estimation, 
uses and abuses. Nat. Rev. Genet. 14, 139–149 (2013). 
22. Herskind, A. M. et al. The heritability of human longevity: A population-
based study of 2872 Danish twin pairs born 1870–1900. Hum. Genet. 97, 
319–323 (1996). 
23. Kaplanis, J. et al. Quantitative analysis of population-scale family trees with 
millions of relatives. Science (80-. ). 175, 171–175 (2018). 
24. Ruby, J. G. et al. Estimates of the Heritability of Human Longevity Are 
Substantially Inflated due to Assortative Mating. (2018). 
doi:10.1534/genetics.118.301613 
25. Skousgaard, S. G. et al. Probability and heritability estimates on primary 
osteoarthritis of the hip leading to total hip arthroplasty: A nationwide 
population based follow-up study in Danish twins. Arthritis Res. Ther. 17, 
(2015). 
26. Willemsen, G. et al. The Concordance and Heritability of Type 2 Diabetes 
in 34,166 Twin Pairs From International Twin Registers: The Discordant 
Twin (DISCOTWIN) Consortium. Twin Res. Hum. Genet. 18, 762–771 
(2015). 
27. Gatz, M. et al. Role of genes and environments for explaining Alzheimer 
disease. Arch. Gen. Psychiatry 63, 168–174 (2006). 
28. Zdravkovic, S. et al. Heritability of death from coronary heart disease: a 36-
year follow-up of 20 966 Swedish twins. J. Intern. Med. 252, 247–54 
(2002). 
29. Tachmazidou, I. et al. Identification of new therapeutic targets for 
osteoarthritis through genome-wide analyses of UK Biobank data. Nat. 
 27 
 
Genet. 51, 230–236 (2019). 
30. Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant 
resolution using high-density imputation and islet-specific epigenome 
maps. Nat. Genet. (2018). doi:10.1038/s41588-018-0241-6 
31. Pilling, L. C. et al. Human longevity is influenced by many genetic variants: 
evidence from 75,000 UK Biobank participants. Aging (Albany. NY). 8, 1–
24 (2016). 
32. Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and 
functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 
258533 (2019). doi:10.1038/s41588-018-0311-9 
33. Vinkhuyzen, A. A. E., Wray, N. R., Yang, J., Goddard, M. E. & Visscher, P. 
M. Estimation and partition of heritability in human populations using 
whole-genome analysis methods. Annu. Rev. Genet. 47, 75–95 (2013). 
34. Barsh, G. S., Copenhaver, G. P., Gibson, G. & Williams, S. M. Guidelines 
for Genome-Wide Association Studies. PLoS Genet. 8, e1002812 (2012). 
35. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and 
genomic data. Nature 562, 203–209 (2018). 
36. Dutta, A. et al. Longer lived parents: Protective associations with cancer 
incidence and overall mortality. Journals Gerontol. - Ser. A Biol. Sci. Med. 
Sci. 68, 1409–1418 (2013). 
37. Dutta, A. et al. Aging children of long-lived parents experience slower 
cognitive decline. Alzheimer’s Dement. 10, S315–S322 (2014). 
38. Atkins, J. L. et al. Longer-Lived Parents and Cardiovascular Outcomes: 8-
Year Follow-Up In 186,000 U.K. Biobank Participants. J. Am. Coll. Cardiol. 
68, 874–5 (2016). 
39. Pilling, L. C. et al. Human longevity: 25 genetic loci associated in 389,166 
UK biobank participants. Aging (Albany. NY). 9, 2504–2520 (2017). 
40. Joshi, P. K. et al. Genome-wide meta-analysis associates HLA-
DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nat. 
Commun. 8, 910 (2017). 
41. RHJ Timmers, P. et al. Genomics of 1 million parent lifespans implicates 
 28 
 
novel pathways and common diseases and distinguishes survival chances. 
1–40 (2019). doi:10.7554/eLife.39856.001 
 
This LifeGen study is a GWAS meta-analysis of parents lifespan using UK 
Biobank plus 25 independent cohorts, and including data on 1 million 
parents’ lifespans. 
 
42. Wright, K. M. et al. A Prospective Analysis of Genetic Variants Associated 
with Human Lifespan. G3 (Bethesda). 9, 2863–2878 (2019). 
43. Keskitalo, K. et al. Association of serum cotinine level with a cluster of 
three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) 
on chromosome 15. Hum. Mol. Genet. 18, 4007–12 (2009). 
44. Timpson, N. J., Greenwood, C. M. T. T., Soranzo, N., Lawson, D. J. & 
Richards, J. B. Genetic architecture: The shape of the genetic contribution 
to human traits and disease. Nat. Rev. Genet. 19, 110–124 (2018). 
45. Deelen, J. et al. Genome-wide association study identifies a single major 
locus contributing to survival into old age; the APOE locus revisited. Aging 
Cell 10, 686–698 (2011). 
46. Deelen, J. et al. Genome-wide association meta-analysis of human 
longevity identifies a novel locus conferring survival beyond 90 years of 
age. Hum. Mol. Genet. 23, 4420–32 (2014). 
47. Broer, L. et al. GWAS of Longevity in CHARGE Consortium Confirms 
APOE and FOXO3 Candidacy. J. Gerontol. A. Biol. Sci. Med. Sci. 1–9 
(2014). doi:10.1093/gerona/glu166 
48. Deelen, J. et al. A meta-analysis of genome-wide association studies 
identifies novel longevity genes. Nat. Commun. (2019). 
doi:10.1038/s41467-019-11558-2 
 
This is the largest GWAS directly studying long-lived participants (aged ≥90 
years) compared to shorter-lived (<65) controls to date. 
 
 29 
 
49. Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide 
association meta-analysis of coronary artery disease. Nat. Genet. 47, 
1121–1130 (2015). 
50. Belloy, M. E., Napolioni, V. & Greicius, M. D. A Quarter Century of APOE 
and Alzheimer’s Disease: Progress to Date and the Path Forward. Neuron 
101, 820–838 (2019). 
51. Sebastiani, P. et al. APOE Alleles and extreme human longevity. Journals 
Gerontol. - Ser. A Biol. Sci. Med. Sci. 74, 44–51 (2019). 
52. Kichaev, G. et al. Leveraging Polygenic Functional Enrichment to Improve 
GWAS Power. Am. J. Hum. Genet. 104, 65–75 (2019). 
53. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-
wide association studies, targeted arrays and summary statistics 2019. 
Nucleic Acids Res. 47, D1005–D1012 (2019). 
54. Yashin, A. I. et al. Genetics of human longevity from incomplete data: New 
findings from the long life family study. Journals Gerontol. - Ser. A Biol. Sci. 
Med. Sci. 73, 1472–1481 (2018). 
55. Martins, R., Lithgow, G. J. & Link, W. Long live FOXO: Unraveling the role 
of FOXO proteins in aging and longevity. Aging Cell 15, 196–207 (2016). 
56. Bae, H. et al. Effects of FOXO3 Polymorphisms on Survival to Extreme 
Longevity in Four Centenarian Studies. Journals Gerontol. - Ser. A Biol. 
Sci. Med. Sci. 73, 1439–1447 (2018). 
57. Revelas, M. et al. Review and meta-analysis of genetic polymorphisms 
associated with exceptional human longevity. Mechanisms of Ageing and 
Development 175, 24–34 (2018). 
58. Giuliani, C., Garagnani, P. & Franceschi, C. Genetics of Human Longevity 
Within an Eco-Evolutionary Nature-Nurture Framework. Circ. Res. 123, 
745–772 (2018). 
59. Day, F. R. et al. Large-scale genomic analyses link reproductive aging to 
hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated 
DNA repair. Nat. Genet. 47, (2015). 
60. Ruth, K. & Murray, A. Lessons from Genome-Wide Association Studies in 
 30 
 
Reproductive Medicine: Menopause. Semin. Reprod. Med. 34, 215–223 
(2016). 
61. Cooper, R., Kuh, D. & Hardy, R. Objectively measured physical capability 
levels and mortality: Systematic review and meta-analysis. BMJ (Online) 
341, 639 (2010). 
62. Willems, S. M. et al. Large-scale GWAS identifies multiple loci for hand grip 
strength providing biological insights into muscular fitness. Nat. Commun. 
8, 16015 (2017). 
63. Jones, G. et al. Sarcopenia and variation in the Human Leukocyte Antigen 
complex. J. Gerontol. A. Biol. Sci. Med. Sci. (2019). 
doi:10.1093/gerona/glz042 
64. Morley, J. E. et al. Brain health: the importance of recognizing cognitive 
impairment: an IAGG consensus conference. J. Am. Med. Dir. Assoc. 16, 
731–9 (2015). 
65. Davies, G. et al. Study of 300,486 individuals identifies 148 independent 
genetic loci influencing general cognitive function. Nat. Commun. 9, 2098 
(2018). 
66. Ritchie, S. J. et al. Polygenic predictors of age-related decline in cognitive 
ability. Mol. Psychiatry (2019). doi:10.1038/s41380-019-0372-x 
67. Logue, M. W. et al. Use of an Alzheimer’s disease polygenic risk score to 
identify mild cognitive impairment in adults in their 50s. Mol. Psychiatry 24, 
421–430 (2019). 
68. Corley, J., Cox, S. R. & Deary, I. J. Healthy cognitive ageing in the Lothian 
Birth Cohort studies: marginal gains not magic bullet. Psychol. Med. 48, 
187–207 (2018). 
69. Black, J. R. & Clark, S. J. Age-related macular degeneration: Genome-
wide association studies to translation. Genetics in Medicine 18, 283–289 
(2016). 
70. Fritsche, L. G. et al. A large genome-wide association study of age-related 
macular degeneration highlights contributions of rare and common 
variants. Nat. Genet. 48, 134–143 (2016). 
 31 
 
71. Barrett, J. H. et al. Genome-wide association study identifies three new 
melanoma susceptibility loci. Nat. Genet. 43, 1108–13 (2011). 
72. Guy, G. P., Machlin, S. R., Ekwueme, D. U. & Yabroff, K. R. Prevalence 
and Costs of Skin Cancer Treatment in the U.S., 2002−2006 and 
2007−2011. Am. J. Prev. Med. 48, 183–187 (2015). 
73. American Cancer Society. Cancer facts and Figuers 2019. (2019). 
74. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human 
diseases and traits. Nat. Genet. 47, 1236–41 (2015). 
75. van Rheenen, W., Peyrot, W. J., Schork, A. J., Lee, S. H. & Wray, N. R. 
Genetic correlations of polygenic disease traits: from theory to practice. 
Nat. Rev. Genet. (2019). doi:10.1038/s41576-019-0137-z 
 
This review defines genetic correlations, summarizes methods, and 
discusses their interpretation and uses with respect to human health 
and disease. 
 
76. Dixon, J. B., Egger, G. J., Finkelstein, E. A., Kral, J. G. & Lambert, G. W. 
‘Obesity paradox’ misunderstands the biology of optimal weight throughout 
the life cycle. Int. J. Obes. 39, 82–84 (2015). 
77. Tchkonia, T. et al. Fat tissue, aging, and cellular senescence. Aging Cell 9, 
667–84 (2010). 
78. Xu, M. et al. Targeting senescent cells enhances adipogenesis and 
metabolic function in old age. Elife 4, e12997 (2015). 
79. Bowman, K., Thambisetty, M., Kuchel, G. A., Ferrucci, L. & Melzer, D. 
Obesity and Longer Term Risks of Dementia in 65-74 Year Olds. Age 
Ageing 1–6 (2019). doi:10.1093/ageing/afz002 
80. Bowman, K. et al. Obesity in Older People With and Without Conditions 
Associated With Weight Loss : Follow-up of 955 , 000 Primary Care 
Patients Editor ’ s Choice. J. Gerontol. A. Biol. Sci. Med. Sci. 72, 203–209 
(2017). 
81. Pignolo, R. J. Exceptional Human Longevity. Mayo Clin. Proc. 94, 110–124 
 32 
 
(2019). 
82. Global Lipids Genetics Consortium et al. Discovery and refinement of loci 
associated with lipid levels. Nat. Genet. 45, 1274–83 (2013). 
83. Congrains, A., Kamide, K., Ohishi, M. & Rakugi, H. ANRIL: Molecular 
mechanisms and implications in human health. International Journal of 
Molecular Sciences 14, 1278–1292 (2013). 
84. Michailidou, K. et al. Association analysis identifies 65 new breast cancer 
risk loci. Nature 551, 92–94 (2017). 
85. Schumacher, F. R. et al. Association analyses of more than 140,000 men 
identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928–936 
(2018). 
86. Rahmioglu, N. et al. Genetic variants underlying risk of endometriosis: 
insights from meta-analysis of eight genome-wide association and 
replication datasets. Hum. Reprod. Update 20, 702–16 (2014). 
87. Springelkamp, H. et al. Meta-analysis of Genome-Wide Association 
Studies Identifies Novel Loci Associated With Optic Disc Morphology. 
Genet. Epidemiol. 39, 207–16 (2015). 
88. Astle, W. J. et al. The Allelic Landscape of Human Blood Cell Trait 
Variation and Links to Common Complex Disease. Cell 167, 1415-
1429.e19 (2016). 
89. Baker, D. J. et al. Naturally occurring p16 Ink4a-positive cells shorten 
healthy lifespan. Nature 530, 184–189 (2016). 
 
This study of a transgenic mouse model was the first to show that removal 
of senescent cells from an adult animal extended lifespan and 
improved some aspects of health. 
 
90. Tchkonia, T. & Kirkland, J. L. Aging , Cell Senescence , and Chronic 
Disease Emerging Therapeutic Strategies. JAMA 320, 1321–1323 (2018). 
 
This manuscript provides an overview of cell senescence, links to aging, 
 33 
 
and future therapeutics. 
 
91. Schmit, S. L. et al. Novel Common Genetic Susceptibility Loci for 
Colorectal Cancer. J. Natl. Cancer Inst. 111, 146–157 (2019). 
92. Xiang, J. F., Yang, L. & Chen, L. L. The long noncoding RNA regulation at 
the MYC locus. Current Opinion in Genetics and Development 33, 41–48 
(2015). 
93. Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell 
strains. Exp. Cell Res. 25, 585–621 (1961). 
94. Broer, L. et al. Meta-analysis of telomere length in 19,713 subjects reveals 
high heritability, stronger maternal inheritance and a paternal age effect. 
Eur. J. Hum. Genet. 21, 1163–1168 (2013). 
95. Telomeres Mendelian Randomization Collaboration et al. Association 
Between Telomere Length and Risk of Cancer and Non-Neoplastic 
Diseases: A Mendelian Randomization Study. JAMA Oncol. (2017). 
doi:10.1001/jamaoncol.2016.5945 
 
This study found that genetic predisposition to longer telomeres increased 
risk of multiple cancers, but reduced risk for some other diseases 
including cardiovascular disease. 
 
96. Codd, V. et al. Identification of seven loci affecting mean telomere length 
and their association with disease. Nat. Genet. 45, 422–427 (2013). 
97. Kuo, C.-L., Pilling, L. C., Kuchel, G. A., Ferrucci, L. & Melzer, D. Telomere 
length and aging-related outcomes in humans: A Mendelian randomization 
study in 261,000 older participants. Aging Cell e13017 (2019). 
doi:10.1111/acel.13017 
98. Maslah, N., Cassinat, B., Verger, E., Kiladjian, J. J. & Velazquez, L. The 
role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and 
other hematological disorders. Leukemia 31, 1661–1670 (2017). 
99. Malik, R. et al. Multiancestry genome-wide association study of 520,000 
 34 
 
subjects identifies 32 loci associated with stroke and stroke subtypes. Nat. 
Genet. 50, 524–537 (2018). 
100. Fortney, K. et al. Genome-Wide Scan Informed by Age-Related Disease 
Identifies Loci for Exceptional Human Longevity. PLOS Genet. 11, 
e1005728 (2015). 
101. Laroumanie, F., Humphrey, J. D. & Madhur, M. S. LNK deficiency 
promotes acute aortic dissection and rupture. JCI Insight 3, (2018). 
102. Hung, R. J. et al. Cross cancer genomic investigation of inflammation 
pathway for five common cancers: Lung, ovary, prostate, breast, and 
colorectal cancer. J. Natl. Cancer Inst. 107, djv246 (2015). 
103. Kuo, C.-L. et al. The Longevity Associated Sh2b3 (LNK) Genetic Variant: 
Selected Aging Phenotypes in 379,758 Subjects. J. Gerontol. A. Biol. Sci. 
Med. Sci. (2019). doi:10.1093/gerona/glz191 
104. Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 
558, 73–79 (2018). 
105. Schlesinger, M. & Bendas, G. Vascular cell adhesion molecule-1 (VCAM-1) 
- An increasing insight into its role in tumorigenicity and metastasis. Int. J. 
Cancer 136, 2504–2514 (2015). 
106. Slack, C. et al. Regulation of lifespan, metabolism, and stress responses 
by the Drosophila SH2B protein, Lnk. PLoS Genet. 6, (2010). 
107. Mair, W. & Dillin, A. Aging and survival: the genetics of life span extension 
by dietary restriction. Annu. Rev. Biochem. 77, 727–54 (2008). 
108. Junnila, R. K., List, E. O., Berryman, D. E., Murrey, J. W. & Kopchick, J. J. 
The GH/IGF-1 axis in ageing and longevity. Nat. Rev. Endocrinol. 9, 366–
376 (2013). 
109. Desbuquois, B., Carré, N. & Burnol, A. F. Regulation of insulin and type 1 
insulin-like growth factor signaling and action by the Grb10/14 and 
SH2B1/B2 adaptor proteins. FEBS Journal 280, 794–816 (2013). 
110. Shiina, T., Hosomichi, K., Inoko, H. & Kulski, J. K. The HLA genomic loci 
map: Expression, interaction, diversity and disease. Journal of Human 
Genetics 54, 15–39 (2009). 
 35 
 
111. Ligthart, S. et al. Genome Analyses of >200,000 Individuals Identify 58 Loci 
for Chronic Inflammation and Highlight Pathways that Link Inflammation 
and Complex Disorders. Am. J. Hum. Genet. 103, 691–706 (2018). 
112. Franchini, M. & Bonfanti, C. Evolutionary aspects of ABO blood group in 
humans. Clin. Chim. Acta 444, 66–71 (2015). 
113. Jin, T. Current understanding on role of the wnt signaling pathway effector 
TCF7L2 in glucose homeostasis. Endocr. Rev. 37, 254–277 (2016). 
114. Locke, A. E. et al. Genetic studies of body mass index yield new insights 
for obesity biology. Nature 518, 197–206 (2015). 
115. Stone, T. W., McPherson, M. & Gail Darlington, L. Obesity and Cancer: 
Existing and New Hypotheses for a Causal Connection. EBioMedicine 30, 
14–28 (2018). 
116. Martin, G. M. & Oshima, J. Lessons from human progeroid syndromes. 
Nature 408, 263–266 (2000). 
117. Oshima, J., Sidorova, J. M. & Monnat, R. J. Werner syndrome: Clinical 
features, pathogenesis and potential therapeutic interventions. Ageing Res. 
Rev. 33, 105–114 (2017). 
118. Pignolo, R. J. et al. Defects in telomere maintenance molecules impair 
osteoblast differentiation and promote osteoporosis. Aging Cell 7, 23–31 
(2008). 
119. Ahmed, M. S., Ikram, S., Bibi, N. & Mir, A. Hutchinson-Gilford Progeria 
Syndrome: A Premature Aging Disease. Mol. Neurobiol. 55, 4417–4427 
(2018). 
120. Nance, M. A. & Berry, S. A. Cockayne syndrome: review of 140 cases. Am. 
J. Med. Genet. 42, 68–84 (1992). 
121. Burla, R., La Torre, M., Merigliano, C., Vernì, F. & Saggio, I. Genomic 
instability and DNA replication defects in progeroid syndromes. Nucleus 9, 
368–379 (2018). 
122. Gonzalo, S., Kreienkamp, R. & Askjaer, P. Hutchinson-Gilford Progeria 
Syndrome: A premature aging disease caused by LMNA gene mutations. 
Ageing Res. Rev. 33, 18–29 (2017). 
 36 
 
123. Scaffidi, P. & Misteli, T. Lamin A-dependent nuclear defects in human 
aging. Science 312, 1059–63 (2006). 
124. Jiang, Y. & Ji, J. Y. Understanding lamin proteins and their roles in aging 
and cardiovascular diseases. Life Sci. 212, 20–29 (2018). 
125. Scheibye-Knudsen, M. et al. Cockayne syndrome group A and B proteins 
converge on transcription-linked resolution of non-B DNA. Proc. Natl. Acad. 
Sci. U. S. A. 113, 12502–12507 (2016). 
126. Lee, J. J. et al. Gene discovery and polygenic prediction from a genome-
wide association study of educational attainment in 1.1 million individuals. 
Nat. Genet. 50, 1112–1121 (2018). 
127. Liu, M. et al. Association studies of up to 1.2 million individuals yield new 
insights into the genetic etiology of tobacco and alcohol use. Nat. Genet. 
51, 237–244 (2019). 
128. Yun, S. & Vincelette, N. D. Update on iron metabolism and molecular 
perspective of common genetic and acquired disorder, hemochromatosis. 
Crit. Rev. Oncol. Hematol. 95, 12–25 (2015). 
129. Pilling, L. C. et al. Common conditions associated with hereditary 
haemochromatosis genetic variants: cohort study in UK Biobank. BMJ 364, 
k5222 (2019). 
130. Tamosauskaite, J. et al. Hereditary Hemochromatosis Associations with 
Frailty, Sarcopenia and Chronic Pain: Evidence from 200,975 Older UK 
Biobank Participants. J. Gerontol. A. Biol. Sci. Med. Sci. In press, (2019). 
131. Telenti, A., Perkins, B. A. & Venter, J. C. Dynamics of an Aging Genome. 
Cell Metab. 23, 949–950 (2016). 
132. Zhang, L. & Vijg, J. Somatic Mutagenesis in Mammals and Its Implications 
for Human Disease and Aging. Annu. Rev. Genet. 52, 397–419 (2018). 
 
This paper reviews the literature on low-abundance somatic DNA mutations 
in cells, in human and animal tissues and new technology that allows 
their assessment, with a focus on their possible functional 
consequences. 
 37 
 
 
133. Risques, R. A. & Kennedy, S. R. Aging and the rise of somatic cancer-
associated mutations in normal tissues. PLOS Genet. 14, e1007108 
(2018). 
134. Blokzijl, F. et al. Tissue-specific mutation accumulation in human adult 
stem cells during life. Nature 538, 260–264 (2016). 
135. Zhang, L. et al. Single-cell whole-genome sequencing reveals the 
functional landscape of somatic mutations in B lymphocytes across the 
human lifespan. PNAS (2019). doi:10.1101/535906 
136. Franco, I. et al. Somatic mutagenesis in satellite cells associates with 
human skeletal muscle aging. Nat. Commun. 9, 800 (2018). 
 
This study investigated somatic mutations in human B lymphocytes. 
Results indicate that spontaneous somatic mutations accumulate 
with age may contribute to both the increased risk for leukemia and 
the functional decline of B lymphocytes in the elderly. 
 
137. Martincorena, I. et al. Somatic mutant clones colonize the human 
esophagus with age. Science (80-. ). 3879, eaau3879 (2018). 
138. Yokoyama, A. et al. Age-related remodelling of oesophageal epithelia by 
mutated cancer drivers. Nature 565, 312–317 (2019). 
139. Fuster, J. J. & Walsh, K. Somatic Mutations and Clonal Hematopoiesis. 
Circ. Res. 122, 523–532 (2018). 
140. Van Den Akker, E. B. et al. Uncompromised 10-year survival of oldest old 
carrying somatic mutations in DNMT3A and TET2. Blood 127, 1512–1515 
(2016). 
141. Andrews, R. M. et al. Reanalysis and revision of the Cambridge reference 
sequence for human mitochondrial DNA. Nat. Genet. 23, 147 (1999). 
142. Stewart, J. B. & Chinnery, P. F. The dynamics of mitochondrial DNA 
heteroplasmy: implications for human health and disease. Nat. Rev. Genet. 
16, 530–42 (2015). 
 38 
 
143. Hutchison, C. A., Newbold, J. E., Potter, S. S. & Edgell, M. H. Maternal 
inheritance of mammalian mitochondrial DNA. Nature 251, 536–8 (1974). 
144. Scheibye-Knudsen, M., Scheibye-Alsing, K., Canugovi, C., Croteau, D. L. 
& Bohr, V. A. A novel diagnostic tool reveals mitochondrial pathology in 
human diseases and aging. Aging (Albany. NY). 5, 192–208 (2013). 
 
This paper describes a novel classification algorithm based on qualitative 
and quantitative characteristics assessing whether a disorder can be 
characterized as mitochondrial. Using this tool, the authors find that 
many of the features of normal aging may be linked to mitochondrial 
dysfunction. 
 
145. Wallace, D. C. et al. Sequence analysis of cDNAs for the human and 
bovine ATP synthase beta subunit: mitochondrial DNA genes sustain 
seventeen times more mutations. Curr. Genet. 12, 81–90 (1987). 
146. Bua, E. et al. Mitochondrial DNA-deletion mutations accumulate 
intracellularly to detrimental levels in aged human skeletal muscle fibers. 
Am. J. Hum. Genet. 79, 469–80 (2006). 
147. Greaves, L. C. et al. Clonal expansion of early to mid-life mitochondrial 
DNA point mutations drives mitochondrial dysfunction during human 
ageing. PLoS Genet. 10, e1004620 (2014). 
148. Picard, M., Wallace, D. C. & Burelle, Y. The rise of mitochondria in 
medicine. Mitochondrion 30, 105–16 (2016). 
149. Trifunovic, A. et al. Premature ageing in mice expressing defective 
mitochondrial DNA polymerase. Nature 429, 417–23 (2004). 
 
This manuscript describes the phenotype of a homozygous knock-in mice 
that expresses a proof-reading-deficient version of PolgA, the 
nucleus-encoded catalytic subunit of mtDNA polymerase. The PolgA 
mouse accumulates point mutations in mitochondrial DNA much 
faster than wild-type and shows reduced lifespan and premature 
 39 
 
onset of ageing-related phenotypes. 
 
150. Kraytsberg, Y. et al. Mitochondrial DNA deletions are abundant and cause 
functional impairment in aged human substantia nigra neurons. Nat. Genet. 
38, 518–20 (2006). 
151. Franco-Iborra, S., Vila, M. & Perier, C. Mitochondrial Quality Control in 
Neurodegenerative Diseases: Focus on Parkinson’s Disease and 
Huntington’s Disease. Front. Neurosci. 12, 342 (2018). 
152. Ferrucci, L., Levine, M. E., Kuo, P. & Simonsick, E. M. Time and the 
Metrics of Aging. Circ. Res. 123, 740–744 (2018). 
153. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies 
predicts complex trait gene targets. Nat. Genet. 48, 481–7 (2016). 
154. Campbell, M. C. & Tishkoff, S. A. African Genetic Diversity: Implications for 
Human Demographic History, Modern Human Origins, and Complex 
Disease Mapping. Annu. Rev. Genomics Hum. Genet. 9, 403–433 (2008). 
155. Kenyon, C. J. The genetics of ageing. Nature 464, 504–512 (2010). 
156. McKay, J. P., Raizen, D. M., Gottschalk, A., Schafer, W. R. & Avery, L. eat-
2 and eat-18 are required for nicotinic neurotransmission in the 
Caenorhabditis elegans pharynx. Genetics 166, 161–9 (2004). 
157. Greer, E. L. & Brunet, A. Different dietary restriction regimens extend 
lifespan by both independent and overlapping genetic pathways in C. 
elegans. Aging Cell 8, 113–127 (2009). 
158. Gingras, A.-C., Raught, B. & Sonenberg, N. eIF4 Initiation Factors: 
Effectors of mRNA Recruitment to Ribosomes and Regulators of 
Translation. Annu. Rev. Biochem. 68, 913–963 (2002). 
159. Lakowski, B. & Hekimi, S. Determination of life-span in Caenorhabditis 
elegans by four clock genes. Science 272, 1010–3 (1996). 
160. Liu, X. et al. Evolutionary conservation of the clk-1-dependent mechanism 
of longevity: Loss of mclk1 increases cellular fitness and lifespan in mice. 
Genes Dev. 19, 2424–2434 (2005). 
161. Bansal, A., Zhu, L. J., Yen, K. & Tissenbaum, H. A. Uncoupling lifespan 
 40 
 
and healthspan in Caenorhabditis elegans longevity mutants. Proc. Natl. 
Acad. Sci. U. S. A. 112, E277 (2015). 
162. Mitchell, S. J. et al. Effects of Sex, Strain, and Energy Intake on Hallmarks 
of Aging in Mice. Cell Metab. 23, 1093–1112 (2016). 
163. Fontana, Luigi; Partridge, Linda; Longo,  valter D. Extending Healthy Life 
Span — From Yeast to Humans. Science (80-. ). 328, 321–326 (2010). 
164. Mattison, J. A. et al. Caloric restriction improves health and survival of 
rhesus monkeys. Nat. Commun. 8, 1–12 (2017). 
165. Kraus, W. E. et al. 2 years of calorie restriction and cardiometabolic risk 
(CALERIE): exploratory outcomes of a multicentre, phase 2, randomised 
controlled trial. lancet. Diabetes Endocrinol. 0, (2019). 
166. Belsky, D. W., Huffman, K. M., Pieper, C. F., Shalev, I. & Kraus, W. E. 
Change in the Rate of Biological Aging in Response to Caloric Restriction: 
CALERIE Biobank Analysis. Journals Gerontol. Ser. A 73, 4–10 (2018). 
167. Leclerc, E. et al. The effect of caloric restriction on working memory in 
healthy non-obese adults. CNS Spectr. 1–7 (2019). 
doi:10.1017/S1092852918001566 
168. Madeo, F., Carmona-Gutierrez, D., Hofer, S. J. & Kroemer, G. Caloric 
Restriction Mimetics against Age-Associated Disease: Targets, 
Mechanisms, and Therapeutic Potential. Cell Metab. 29, 592–610 (2019). 
169. Most, J., Tosti, V., Redman, L. M. & Fontana, L. Calorie restriction in 
humans: An update. Ageing Res. Rev. 39, 36–45 (2017). 
170. Laplante, M. & Sabatini, D. M. mTOR signaling at a glance. J. Cell Sci. 
122, 3589–3594 (2009). 
171. Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in 
genetically heterogeneous mice. Nature 460, 392–395 (2009). 
172. Mannick, J. B. et al. TORC1 inhibition enhances immune function and 
reduces infections in the elderly. Sci. Transl. Med. 10, eaaq1564 (2018). 
173. Dowling, R. J. O., Topisirovic, I., Fonseca, B. D. & Sonenberg, N. 
Dissecting the role of mTOR: Lessons from mTOR inhibitors. Biochimica et 
Biophysica Acta - Proteins and Proteomics 1804, 433–439 (2010). 
 41 
 
174. Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: Results from 
a first-in-human, open-label, pilot study. EBioMedicine 40, 554–563 (2019). 
175. Butler, P. G., Wanamaker, A. D., Scourse, J. D., Richardson, C. A. & 
Reynolds, D. J. Variability of marine climate on the North Icelandic Shelf in 
a 1357-year proxy archive based on growth increments in the bivalve 
Arctica islandica. Palaeogeogr. Palaeoclimatol. Palaeoecol. 373, 141–151 
(2013). 
176. Weismann, A., Poulton Sir, E. B., Schönland, S. & Shipley Sir, A. E. (Arthur 
E. Essays upon heredity and kindred biological problems. v.1, (Clarendon 
Press, 1891). 
177. Fabian, D. & Flatt, T. The Evolution of Aging. Nat. Educ. Knowl. 3, 9 
(2011). 
178. Medawar, P. B. An Unsolved Problem of Biology. Evolution in Health and 
Disease 24 (1951). doi:10.1016/S0140-6736(00)99799-X 
179. Partridge, L. & Barton, N. H. Optimally, mutation and the evolution of 
ageing. Nature 362, 305–311 (1993). 
180. Williams, G. C. Pleiotropy, Natural Selection, and the Evolution of 
Senescence. Evolution (N. Y). 11, 398 (2006). 
181. Campisi, J. Senescent cells, tumor suppression, and organismal aging: 
good citizens, bad neighbors. Cell 120, 513–22 (2005). 
182. Kirkwood, T. B. L. Evolution of ageing. Nature 270, 301–304 (1977). 
183. Pride, H. et al. Long-lived species have improved proteostasis compared 
to phylogenetically-related shorter-lived species. Biochem. Biophys. Res. 
Commun. 457, 669–675 (2015). 
184. Krzywinski, M. Circos Table Viewer - Circular Visualization of Tabular Data 
// with Circos - Circular Genome Data Visualization. (2019). Available at: 
http://mkweb.bcgsc.ca/tableviewer/visualize/. (Accessed: 5th March 2019) 
185. Pruim, R. J. et al. LocusZoom: regional visualization of genome-wide 
association scan results. Bioinformatics 26, 2336–7 (2010). 
186. Pingault, J. B. et al. Using genetic data to strengthen causal inference in 
observational research. Nat. Rev. Genet. 19, 566–580 (2018). 
 42 
 
 
 
 
 
Acknowledgements 
D.M. and L.C.P. are supported by the University of Exeter Medical School and 
additionally by the University of Connecticut School of Medicine. This work is 
supported in part by the UK Medical Research Council (grants MR/M023095/1 and 
MRS009892/1). This work was also supported in part by the Intramural Research 
Program at the National Institute on Aging. 
 
Competing interests 
The authors declare no competing interests. 
 
RELATED LINKS 
The CHARGE Consortium http://www.chargeconsortium.com/  
The longevity consortium https://www.longevityconsortium.org/ 
Online Mendelian Inheritance of Man (OMIM) https://www.omim.org 
GWAS catalog https://www.ebi.ac.uk/gwas/ 
 
 
  
 43 
 
Box 1. Slowing ageing in laboratory models. 
Interventions in laboratory models can delay or reverse specific aspects of ageing. 
These models provide robust insights into ageing mechanisms, which might be 
conserved across species.  
 
[b1] Targeting nutrient sensing and dietary restriction  
A number of genetic manipulations can markedly prolong survival in 
Caenorhabditis elegans. Long-lived genetic mutans may result from modulation of 
different, independent biological pathways. For example, daf-2 affects nutrient 
sensing through modulation of insulin–insulin-like growth factor 1 (IGF-1) signalling 
and upregulation of autophagy 155; eat-2 codes for a defective nicotinic 
acetylcholine receptor causing impaired pharyngeal pumping and a genetic form 
of caloric restriction 156,157; knockdown of ife-2 increases lifespan by 
downregulating protein translation 158; and knockdown of the clock gene clk-1 
affects longevity by impairing mitochondrial electron transport chain activity, 
therefore reducing oxidative stress 159,160. However, only the modulation of insulin–
IGF-1 (via daf-2) shows increased health span, and in all four long-lived mutants 
the period of frailty is disproportionally extended compared to lifespan161.  
Restricting calorie intake while maintaining necessary micronutrient intakes 
produces lean animals and improves functioning and lengthens life in many but 
not all mouse strains162. Dietary restriction increases longevity by modulating the 
expression of growth factors, such as IGF-1, and affecting the mammalian target 
of rapamycin (mTOR) and ribosomal protein S6 kinase (S6K) signalling 
pathway163. The effectiveness of dietary restriction in promoting health span and 
life span seems to be evolutionally conserved in yeast, worms, flies and some 
mouse strains162. However, in primates, the effect of caloric restriction varied 
between experiments, with some detectable positive effects on metabolic disease 
prevention, which may be partially related to the effect of the intervention on body 
composition164. However, whether such positive effects of metabolic controls are 
strong enough to affect longevity is still in question.  
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Caloric restriction in healthy, non-obese humans has beneficial effects on multiple 
cardiometabolic risk factors, might prevent decline of memory and is associated 
with slowing down of a proxy biomarker of biological ageing165,166,167, although 
these findings need confirmation with longer follow-up times. Several nutritional 
interventions are under development to delay ageing, including different forms of 
caloric restriction, fasting and calorie restriction mimetics, agents that mimic the 
beneficial effects of dietary restriction without necessarily restricting calories, thus 
avoiding detrimental impact168,169.  
 
[b2] Targeting mTOR 
The mTOR signalling pathway, a central regulator of cell metabolism, growth, 
proliferation and survival170, has been extensively implicated in ageing. 
Rapamycin, a licensed immunosuppressive drug targeting mTOR, extended 
healthspan and lifespan even in already older mice, in randomized trials in three 
different studies171. A human trial of low-dose rapamycin analogue reported 
enhanced immune function and a reduction in infections but the potential effect on 
longevity in humans is unknown172. The effects of rapamycin include increasing 
autophagy, which may counteract immune senescence by affecting energy 
metabolism, organelle recycling, as well as the fate and function of immune cells 
173.  
 
[b3] Targeting senescent cells 
A wide range of biological stresses that cause cell damage can lead to cellular 
senescence, in which cells become unable to replicate, secrete large quantities of 
cytokines, chemokines, proteases and growth factors, and develop resistance to 
apoptosis90. A targeted removal of senescent cells expressing p16ink4a resulted in 
the reversal of several features of ageing in mouse models89. The development of 
senolytic molecules that can selectively induce apoptosis of senescent cells is an 
active area of investigation, with a ‘first in man’ clinical trial in idiopathic pulmonary 
fibrosis recently reporting efficacy and safety174. 
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Box 2. Evolutionary theories of ageing  
Lifespans of different animal species vary enormously, from less than 1 day in 
mayflies to more than 400 years in ocean quahog clams175, and this variation must 
ultimately arise from evolved differing abilities to adapt to the surrounding 
environment and respond to stress, both abilities that are likely genetically 
encoded.  
The early theory of group selection argued that ageing is a genetically encoded 
adaptive trait that increases mortality in individuals with declining reproductive 
potential, thereby freeing up resources for the younger generation to 
reproduce176. This theory was soon abandoned by the original author because of 
evidence that natural selection is most effective at the individual level even when 
it may conflict with the interests of the species177. Also, no organism-level 
‘programmed death gene’ has been found. Currently, the most widely accepted 
theories of ageing are the mutation accumulation theory, the antagonistic 
pleiotropy theory and the disposable soma theory. 
The mutation accumulation theory proposes that organisms accumulate damaging 
germline mutations that are expressed only in the post-reproductive period of life, 
as these mutations would not be eliminated by earlier selective pressures178. This 
theory interprets differences in lifespan between different mammal species as 
related to differences in age of sexual maturity. Huntington disease provides a 
prominent example. However, the rapid post-reproduction increase in death rates 
that would be expected according to this theory has not been detected in humans 
or in animal species179.  
The antagonistic pleiotropy theory argues that some mutations selected because 
they are beneficial to early fitness become harmful late in life, causing ageing180. 
Cell senescence pathways may provide examples of antagonistic pleiotropy: 
programmed senescence occurs during normal mammalian development, protects 
against cancer and promotes wound healing at younger ages but contributes to 
degenerative chronic disease at older ages181. 
The disposable soma theory states that given the availability of limited resources, 
ageing arises from evolutionary trade-offs between growth and reproduction on the 
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one hand and repair mechanisms on the other182. This theory is consistent with 
evidence that long-lived species such as humans evolved by developing more 
sophisticated and effective, albeit not unlimited, repair mechanisms. For example, 
comparative studies have found that the capacity to recycle deteriorated 
macromolecules and organelles by autophagy correlates with life-span across 
species183. This theory is also consistent with the current consensus that ageing 
results from the accumulation of unrepaired cellular and molecular damage1832. 
Human resilience mechanisms were likely selected to be robust enough to match 
the high environmental pressures that drove human evolution. The very recent 
dramatic decline of environmental pressures has extended survival beyond the 
previous resilience ‘warranty period’. Contemporary environments allow lengthy 
survival after the reproductive period, with an eventual increasing predominance 
of damage over repair. 
 
Figure 1. Genetic overlap between age-related chronic diseases and parental 
longevity, based on correlations between whole-genome association 
results.  
Genetic correlations are from linkage disequilibrium (LD) score regression 
methods using available genome-wide association study (GWAS) summary 
statistics. Statistically significant correlations are indicated with an asterisk (single 
for nominal P<0.05 significance, double indicates significant after Bonferroni 
correction for 36 tests in this analysis). Ordered by similarity using hierarchical 
clustering (Supplementary table 3 for details). 
 
Figure 2. Selected loci with correlated variants associated with three or more 
age-related diseases or lifespan.  
Nine loci identified as hotspots for at least three major age-related diseases or 
lifespan in genome-wide association study (GWAS) that included multiple 
correlated (R2>0.6) genetic variants (see Supplementary tables 4 and 5 for details). 
The lipid-related variants LPA, LDLR and APOE were excluded for simplicity. 
Genes are shown on the left, with each ‘link’ to a disease on the right indicating a 
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GWAS-identified signal. Lifespan refer to parental lifespan. AD, Alzheimer 
disease; CAD, coronary artery disease; CKD, chronic kidney disease; OA, 
osteoarthritis. Circos table viewer was used for visualization184. 
 
Figure 3. Disease-associated genetic variants in the 9p21.3 locus, by effect 
size of association with parents’ lifespan.  
LocusZoom185 plot of known disease-associated variants in the 9p21.3 locus, 
containing genes CDKN2A (p16ink4a), CDKN2B (p15ink4b) and CDKN2B-AS1 (the 
lncRNA ANRIL). Genetic variants are labelled with the trait(s) they are reported to 
be associated with in published genome-wide association study (GWAS) (see 
Supplementary Table 6 for details). The y-axis shows the association (-log10 p-
value) with parental lifespan from the 2019 LifeGen GWAS41. The variant in purple 
(rs1556516) is the lead signal at this locus from the parents’ lifespan analysis. The 
other variants are coloured according to their correlation with rs1556516 in 1000 
Genomes European ancestry data (v. Nov 2014). 
 
Figure 4. Diagram of the major influences and mechanisms of human ageing.  
The emerging picture from genetic studies of human ageing supports the 
hypothesis that ageing is driven by the balance of damage and repair processes. 
There is genetic evidence for the importance of several damage pathways in 
humans. Damage can be intrinsic, for example, through somatic mutations arising 
during cell division. Also important are health behavioural risk factors such as 
smoking and obesity, which are also influenced by gene–environment interactions. 
The net impact of damage depends on repair and response mechanisms. At the 
cellular level, complete repair can yield undamaged cells (not shown, to simplify 
the figure). By contrast, unrepaired damage can lead to cell death (apoptosis), 
preventing cancers but leading to depletion of stem cells and loss of regenerative 
capacity. Cells with somatic oncogene mutations can survive and replicate, 
sometime producing cancers. Alternatively, damaged cells can enter senescent 
states and produce a secretory senescence phenotype (SASP), resulting in 
inflammation and reduced repair that contributes to degenerative diseases90. 
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These mechanisms can result in reduced repair and increasing incidence of 
chronic diseases of ageing but with decreased cancer risks, or vice versa. This 
ageing versus cancer trade-off is evident for several of the loci described, notably 
in the 9p21 cell cycle- and senescence-related locus, telomere variation and in the 
SH2B3 locus. 
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Table 1. Genetic variants associated with parental lifespan  
 
 
 
a) Effect = years added to lifespan of parents (from LifeGen analysis41).  
b) "rsID (effect allele)" and "Effect" information from LifeGen analysis41. The AncestryDNA analysis 
may have reported a different lead SNP for the same locus.  
c) HYKK neighbouring gene to CHRNA3 and CHRNA5. 
d) variant located between ATXN2 and BRAP, but is correlated (R2>0.8) with missense variant in 
SH2B3.  
e) located in the intron of gene FURIN. 
f) Significantly associated with father's lifespan, not mother's 
g) Significantly associated with mother's lifespan, not father's 
h) not exhaustive list. 
 
 
Study rsID Effecta Mapped Gene name Variant Associated  
  (effect allele)   gene(s)   position disease 
Loci significant in bothb:             
UKB + LifeGen cohorts41 rs429358 (T) 1.06 APOE Apolipoprotein E missense Cardiometabolic, 
dementia 
UKB + AncestryDNA42  rs10455872 (A) 0.76 LPA Lipoprotein A intronic Cardio-metabolic 
  rs8042849 (T)c 0.44 CHRNA3/5 Cholinergic receptor nicotinic alpha 
3/5 subunit 
intronic Smoking-related 
  rs142158911 (A) 0.36 LDLR Low density lipoprotein receptor intergenic Cardio-metabolic 
  rs11065979 (C)d 0.28 SH2B3 .. 
ATXN2 
SH2B adaptor protein 3 .. Ataxin 2 intergenic Cardio-metabolic, 
cancers, 
autoimmunityh 
  rs1556516 (G) 0.25 CDKN2B-
AS1 
CDKN2B antisense RNA 1 intronic Cardio-metabolic, 
cancersh 
Loci significant in only: 
      
UKB + LifeGen cohorts rs34967069 (T) 0.56 HLA-DQA1 Major histocompatibility complex, 
class II, DQ alpha 1 
intergenic Autoimmune 
  rs1230666 (G) 0.32 MAGI3 Membrane associated guanylate 
kinase, WW and PDZ domain 
containing 3 
intronic Autoimmune 
  rs12924886 (A) 0.28 HP Haptoglobin intergenic Cardio-metabolic 
  rs1275922 (G) 0.26 KCNK3 Potassium two pore domain 
channel subfamily K member 3 
intronic Cardio-metabolic 
  rs6224 (G)e 0.25 FURIN/FES Furin, paired basic amino acid 
cleaving enzyme 
intronic Cardio-metabolic 
  rs61348208 (T) 0.23 HTT Huntingtin intronic 
 
Loci significant in only:             
UKB + AncestryDNA  rs7844965 (G)f 0.25 EPHX2 Epoxide Hydrolase 2 intronic 
 
  rs4774495 (G)f 0.23 SEMA6D Semaphorin 6D intronic   
 rs599839 (G)f 0.21 CELSR2 .. 
PSRC1 
Cadherin EGF LAG Seven-Pass G-
Type Receptor 2 .. Proline And 
Serine Rich Coiled-Coil 1 
intergenic Cardio-metabolic 
 rs3131621 (G)f 0.20 MICA .. 
MICB 
MHC Class I Polypeptide-Related 
Sequence A .. B 
intergenic  
  rs15285 (G)f 0.18 LPL Lipoprotein Lipase 3' UTR Cardio-metabolic 
  rs9872864 (G)g 0.14 IP6K1 Inositol Hexakisphosphate Kinase 1 intronic 
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Glossary  
 
Genome-wide association study 
(GWAS) A study that involves genotyping large numbers of participants to identify 
statistical associations between genetic variants and traits of interest.  
 
Somatic mutations 
Changes to the genetic code arising from errors during DNA damage repair, DNA 
replication, or mitosis, occurring in somatic (non-germline) tissues132. 
 
Healthspan 
The period of life free from disease and functional limitations14. 
 
Heritability 
The proportion of variance in a phenotype that can be attributed to genetic 
differences among individuals in a given population. Narrow-sense heritability 
estimates additive genetic effects. Broad-sense heritability includes both additive 
and dominance effects186. 
 
Polygenic risk score 
Individual-level scores that summarize genetic risk (or protection) for a given 
phenotype. For each person a score is computed by counting the number of effect 
alleles (genetic variants) - weighted by their effect – the person carries. A polygenic 
score is computed by summing scores from a large number, potentially all, of the 
variants in the genome186. 
 
Linkage disequilibrium  
(LD) Non-random associations between alleles at different loci186. 
 
Mendelian randomization  
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A method that uses single nucleotide polymorphisms (SNPs) associated with an 
exposure as instruments to probe the causal nature of the relationship between 
this exposure and an outcome of interest186. 
 
Antagonistic pleiotropy 
Theory arguing that some mutations are selected because they are beneficial to 
early-life fitness but become harmful later in life, thus causing ageing. 
 
Clonal expansions 
The production of daughter cells from a single parent cell, all sharing a particular 
characteristic or trait. 
 
 
